🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Roswell Park, an Exceptional place! youtu.be/S_1c-y5-DzI?si…

Can a cfDNA fragmentomic assay assist in lung cancer screening? - prospective case-control study in >900pts - 84% sensitivity, across stages - (+LDCT)=⬇️no. needed to screen to just 76 Next step validate in prospective cohorts Cancer Discovery OncoAlert #LCSM aacrjournals.org/cancerdiscover…

Surgical Robot Transformer (SRT): Imitation Learning for Surgical Tasks Chelsea Finn Ji Woong Kim Johns Hopkins University Stanford University #roboticSurgery #MedEd #MEDX #Surgery #robotics surgical-robot-transformer.github.io

Love this approach - "Trailblazer" in Cancer Cell. Neoadjuvant chemo-ICI in marginally resectable patients. Led to 25% resection rate and good EFS/OS in both arms. Surgery and RT both safe. Shouldn't we consider giving our best therapy up front?

I think we are fooling ourselves if we think that anatomic staging with CT/PET/brain MR in unresectable stage III does much to reduce the proportion of patients with underlying micrometastatic disease, especially in EGFR-mutated disease! So many of these patients even with

We have these data from CM816. Return to baseline QoL occurs regardless of surgical access or extent of surgery. These are not really as relevant considerations as the importance of getting to surgery and achieving an R0!

Are we ready for a world where our data is exposed at a glance? Caine Ardayfio 🐧 and I offer an answer to protect yourself here: tinyurl.com/meet-ixray

Free scientific illustrations for biologists! 😍 NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations! all freely available in the public domain. Retweet and spread the message! bioart.niaid.nih.gov

Over 50% of patients under 60 in California are getting TAVR. This is absurd! Huge shoutout to Jo Chikwe and team for exposing the alarming truth: TAVR has a 250% higher risk of death in 5 years compared to SAVR. annalsthoracicsurgery.org/article/S0003-…

.Josh Allen found the crease and trusted his feet. 💨 Uncharacteristic mistakes by the Chiefs' defense opened a running lane to victory. #NFLTurningPoint on ESPN+

Curious to see how those periop vs neoadj debates go now that OS is positive for CM816! Excellent news for patients and health care systems! Congrats to the CM816 team brilliantly led by the wonderful ⁦Patrick Forde⁩!!! ⁦IASLC⁩ ⁦AATS⁩ news.bms.com/news/corporate…

Reposting on day that it was announced neoadjuvant only chemo-nivolumab delivers a long term survival benefit in surgically resectable lung cancer, 3 doses of therapy (compared to potentially 16+ in other perioperative/adjuvant immunotherapy regimens) #lcsm

Shankar Siva Elliot Servais, MD, FACS Percy Lee MD Biniam Kidane Brendon Stiles Drew Moghanaki raja flores Tim Kruser donington Gerry Hanna Kristin Higgins Andrea Mckee Andrea Borondy Kitts Ben Solomon Solange Peters Prof Tom John Medical Oncology Group of Australia (MOGA) H. Jack West, MD, FASCO Corinne Faivre-Finn Jonathan Spicer MD PhD Jarushka Naidoo M.Provencio ascopubs.org/doi/10.1200/JC… Improved EFS for N2 disease in CheckMate 77T. Also in NADIM & NADIM2 trials. Lots to be done to improve the outcomes for pts w stage III NSCLC who are not surgical candidates. Not sure we need to be arguing pts who are surgical candidates shouldn’t have it

1/ The Dutch ESLUNG study is potentially the largest prospective registry (n=2,183) evaluating outcomes for stage I NSCLC treated with minimally invasive surgery or SABR. Their non-randomized data, when propensity-matched, show similar findings to those previously reported by the

Dr. Linda Martin (Linda Martin) presented the surgical outcomes of the Alliance AFT-46 trial at #AATS2025. AFT-46 is chemo / durva followed by surgery for stage IIIA/IIIB N2 NSCLC. This is a really special study for our field — the rare investigator-initiated multi-center

Remarkable results for neoadj chemo-immunotherapy in locally advanced, N2/N3, lung cancer. 75% curative resections w v high pCR. Notably >40% of pts treated had high PD-L1 (unselected would be ~25-30%) but the boundary for lung surgery continues to chase the horizon #LCSM

Our team BCM_Surgery BCM Cardiothoracic Surgery Residency The Lung Institute at Baylor Medicine BCMHouston at Baylor College of Medicine has been performing complex esophageal reconstruction to create GI continuity for patients with a multidisciplinary team that includes microvascular surgeons, vocal cord renervation

Why is CM816 so important? After Patrick Forde beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…

AIM-HIGH trial published in Lancet Molecular high-risk stage IA-IIA NSCLC as determined by 14-gene assay with improved survival with adjuvant chemo. It is not often we see survival curves like this in early stage lung cancer. thelancet.com/journals/lanre…

Excited to share our latest work presented at the AACR AI/ML 2025 conference in Montreal! 🌟 We developed a multimodal LLM-driven framework for precision risk prediction in lung cancer surgery, outperforming surgeons and model baselines with an AUC of 0.81. By fusing clinical,